| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | - | 1,000,000 | - |
| Research and development | 2,425,551 | 1,884,907 | 1,886,076 | 1,727,033 |
| General and administrative | 1,380,905 | 2,344,513 | 1,963,346 | 1,801,632 |
| Total operating expenses | 3,806,456 | 4,229,420 | 3,849,422 | 3,528,665 |
| Loss from operations | -3,806,456 | -4,229,420 | -2,849,422 | -3,528,665 |
| Other income | 0 | 720,102 | - | - |
| Foreign exchange gain (loss) | 30,652 | 18,196 | -152,884 | 23,110 |
| Loss before provision for income taxes | -3,775,804 | -3,491,122 | -3,002,306 | - |
| Provision for income taxes | 0 | - | 158,400 | - |
| Net loss | -3,775,804 | -3,491,122 | -3,160,706 | -3,505,555 |
| Net (loss) income per share, basic | -0.95 | -0.89 | -1.56 | -0.7 |
| Net (loss) income per share, diluted | -0.95 | -0.89 | -1.56 | -0.7 |
| Weighted average shares outstanding, basic | 3,965,220 | 3,921,641 | 2,022,818 | 5,037,508 |
| Weighted average shares outstanding, diluted | 3,965,220 | 3,921,641 | 2,022,818 | 5,037,508 |
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Sonnet BioTherapeutics Holdings, Inc. (SONN)